当前位置: 首页 >> 检索结果
4. Safe Sleep Video Intervention via Text Messaging to Low-Income Families: The SMARTER Randomized Clinical Trial.
作者: Rachel Y Moon.;Eve R Colson.;Fern R Hauck.;Ann L Kellams.;Margaret G Parker.;Stephen M Kerr.;Nicole L Geller.;Katherine E Boguszewski.;Scarlett L Bellamy.;Marc T Kiviniemi.;Michael J Corwin.
来源: JAMA. 2026年
Although safe sleep practices reduce the risk of sudden unexpected infant death, US rates of adherence remain low, particularly among low-income families.
12. Intra-Arterial Alteplase After Successful Endovascular Reperfusion in Acute Stroke: The PEARL Randomized Clinical Trial.
作者: .;Xinguang Yang.;Xiongjun He.;Yongteng Xu.;Dong Pan.;Kaifeng Li.;Yanting Chen.;Yingying Zhu.;Yuesong Pan.;Tingyu Yi.;Min Zhang.;Huiyuan Peng.;Weidong Huang.;Dengxing Li.;Jiyun Feng.;Junbin Chen.;Weiheng Lu.;Bin Liao.;Yituan Xie.;Baogong Liao.;Lei Yang.;Longchong Tang.;Bin Han.;Yanchao Liu.;Peijian Lin.;Jixing Chen.;Yanling Liang.;Di Li.;Guohu Weng.;Hanning Huang.;Hao Li.;Chaoqun Li.;Zhiqiang Peng.;Hongzhuang Li.;Baixuan He.;Ruiqi Xue.;Mingyi Bao.;Haoyang Sun.;Hongbiao Hou.;Hongxing Zhou.;Yibin Xiao.;Jie Li.;Wanzhou Zhang.;Xi Chen.;Wei Yan.;Yaxuan Pi.;Zhenhong Deng.;Jinyuan Wang.;Dongshu Xie.;Mengqi Liu.;Honghong Li.;Qingxia Peng.;Wenli Fang.;Xuejing Lin.;Ziyi Chen.;Haiwei Li.;Yuxi Lin.;Queran Lin.;Songhua Xiao.;Zhongrong Miao.;Duolao Wang.;Thanh N Nguyen.;Raul G Nogueira.;Yajie Liu.;Yamei Tang.; .
来源: JAMA. 2025年334卷19期1728-39页
Functional outcomes in patients with acute ischemic stroke due to large-vessel occlusion who undergo thrombectomy remain suboptimal, and the benefits of intra-arterial alteplase after thrombectomy remain uncertain.
13. Insulin Costs and Use by Medicare Beneficiaries After the Inflation Reduction Act Out-of-Pocket Cap.
作者: Rebecca Myerson.;Nam Hyo Kim.;John Romley.;Dima Mazen Qato.;Ying Cao.;Erin Trish.;Anne L Peters.;Dana Goldman.
来源: JAMA. 2026年336卷1期25-34页
The Inflation Reduction Act capped out-of-pocket costs for insulin at $35 per 30-day supply for Medicare beneficiaries in 2023; the impact on insulin access and use is not known.
14. Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.
作者: Brendon L Neuen.;Vlado Perkovic.;Rajiv Agarwal.;David Z I Cherney.;Carolyn S P Lam.;Christoph Wanner.;Katherine R Tuttle.;Pantelis Sarafidis.;Jonathan Barratt.;Anna Burgner.;Xiangmei Chen.;Alfredo Chew-Wong.;Vladimir A Dobronravov.;Jürgen Floege.;Kieran McCafferty.;Masaomi Nangaku.;David Packham.;Evangelos Papachristou.;Pablo E Pergola.;Marijn M Speeckaert.;Arunkumar Subbiah.;Sydney C W Tang.;Shuifu Tang.;See Cheng Yeo.;Niels Jongs.;J David Smeijer.;Mario Berger.;Meike Brinker.;Rania Dayoub.;Jay Elliott.;Na Li.;Katharina Mueller.;Nicole Rethemeier.;Marina Yael Finkelsztein.;Hiddo J L Heerspink.; .
来源: JAMA. 2026年336卷3期224-235页
Glomerular diseases are a leading cause of chronic kidney disease (CKD) and kidney failure. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces the risk of kidney function loss in CKD, but its effects in individuals with CKD due to glomerular diseases are uncertain.
16. Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
作者: Jamie E Chaft.;Zhuoxin Sun.;Charles M Rudin.;Onkar V Khullar.;Charles B Simone.;Kurt Oettel.;David Kozono.;Rajitha Sunkara.;Bryan Faller.;James M Isbell.;Vladimir Hugec.;Asheesh Shipstone.;Eric C McGary.;Jeffrey M Clarke.;Ashita Talsania.;Li Ding.;Ramaswamy Govindan.;Jacob M Sands.;John V Heymach.;Luis E Raez.;Shakun M Malik.;Thomas E Stinchcombe.;Sumithra J Mandrekar.;Jeffrey Bradley.;David E Gerber.;Everett Vokes.;David Gandara.;Charles Staley.;Suresh S Ramalingam.
来源: JAMA. 2026年336卷6期464-472页
Preoperative and perioperative nivolumab improve event-free survival in resectable non-small cell lung cancer. The role of adjuvant nivolumab after upfront surgery is unknown.
17. Adverse Pregnancy Outcomes and Sedentary Behavior, Light-Intensity Physical Activity, and Daily Steps.
作者: Bethany Barone Gibbs.;Jaemyung Kim.;Jacob Gallagher.;Melissa A Jones.;Alex H Crisp.;Katrina Wilhite.;Karina Smith.;Sabera Rahman.;Alexis Thrower.;Janet M Catov.;Christopher E Kline.;Maisa Feghali.;Donna Santillan.;Mark Santillan.;Iqra Sheikh.;Bridget Zimmerman.;Kara M Whitaker.
来源: JAMA. 2026年336卷2期135-143页
Although moderate- to vigorous-intensity physical activity is recommended to reduce the risk of adverse pregnancy outcomes, associations between lower-intensity activities and adverse pregnancy outcomes are not established.
19. Adjunctive Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke: The CHOICE-2 Randomized Clinical Trial.
作者: Arturo Renú.;María Dolores Fernández-Couto.;Patricia de la Riva.;Raquel Delgado-Mederos.;María Herrera.;Ana Morales.;Mikel Terceño.;Nicolás López-Hernández.;Mario Martínez-Galdámez.;Laura Dorado.;Pedro Vega.;Lluis Morales-Caba.;Eva González.;Maitane Alonso.;Pedro Barredo Benítez.;Rebeca Bermejo.;Andrea Cabero-Arnold.;José María Cabrera-Maqueda.;Martha Vargas.;Ángel Calleja Bonilla.;Sergio Calleja.;José Díaz-Pérez.;Salvatore Rudilosso.;Antonio Doncel-Moriano.;María José Feal.;José Ignacio Gallego.;Paola Hurtado.;Carlos Laredo.;Laura Llull.;Inés Bartolomé.;Alberto Martínez-Calvo.;Álvaro Ortega-Sánchez.;Alejandro Rodríguez-Vázquez.;Isabel Rodríguez-Caamaño.;Alba Singla.;Yolanda Silva.;Diana Tarruella Hernández.;Laura Oleaga.;Luis San Román Manzanera.;Joaquín Serena.;María Mar Freijo.;Natalia Pérez de la Ossa.;Mar Castellanos.;Juan Francisco Arenillas-Lara.;Ferran Torres.;Enrique C Leira.;Sergio Amaro.;Xabier Urra.;Ángel Chamorro.; .
来源: JAMA. 2026年335卷21期1859-1869页
Despite high recanalization rates with endovascular thrombectomy for acute ischemic stroke due to large vessel occlusion, functional outcomes remain suboptimal. The benefit of adjunctive intra-arterial thrombolysis after successful thrombectomy is uncertain.
20. Cardiac Resynchronization Therapy: A Review.
作者: Caique M Ternes.;Jitae A Kim.;Anirban Basu.;Kenneth A Ellenbogen.;Mihail G Chelu.
来源: JAMA. 2026年335卷20期1796-1807页
Heart failure (HF) affects more than 64 million individuals worldwide, and acute HF is associated with 1-year mortality rates of 23.6% in North America and Europe. Cardiac dyssynchrony from conduction system disease may cause HF progression, particularly in patients with left ventricular (LV) systolic dysfunction.
|